PDMR Dealings
22/08/2025 15:36
RNS Number : 4924W Oxford Biomedica PLC 22 August 2025 PDMR Dealing Oxford, UK - 22 August 2025: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that Kay Davies, a Non-Executive Director of the Company, purchased 4,563 shares at £4.36 per share on 11 August 2025 and disposed the same number (4,563) at £5.0040 per share on 18 August 2025. The purchase of shares occurred during a closed period as a result of an administrative error by the PDMR's financial advisers. Accordingly, the transaction was executed on behalf of the PDMR without her immediate knowledge. The transaction was subsequently reversed, with the same number of shares sold as had originally been purchased. Upon being informed of the trade, the PDMR promptly escalated the matter to OXB, who in turn notified the FCA without delay. As a gesture of goodwill, the PDMR has confirmed that any gains arising from the trade will be donated to a charity of their choice. The below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the transaction.
| 1. | Details of thePerson Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||
| a) | Name | Kay Davies | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Non-Executive Director | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Date of the transaction | 2025-08-11 | ||||
| b) | Description of the financial instrument | Ordinary Shares of 50 pence each | ||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||
| d) | Nature of the transaction | Purchase of Shares | ||||
| e) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
| f) | Currency | GBP - British pound | ||||
| g) | Price(s) and volumes(s) |
| ||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 4,563 £4.36 £19,894.68 | ||||
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||
| a) | Name | Kay Davies | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Non-Executive Director. | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Name | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Date of the transaction | 2025-08-18 | ||||
| b) | Description of the financial instrument | Ordinary Shares of 50 pence each | ||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||
| d) | Nature of transaction | Sale of shares | ||||
| e) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
| f) | Currency | GBP - British pound | ||||
| g) | Price(s) and volumes(s) |
| ||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 4,563 £5.0040 £22,833.34 | ||||